Bridgeway Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$87.2K Sell
71,483
-390
-0.5% -$1.6K ﹤0.01% 1145
2026
Q2
$702K Hold
71,873
– – 0.01% 793
2026
Q1
$400K Buy
71,873
+6,000
+9% +$45.7K 0.01% 861
2025
Q4
$485K Buy
65,873
+31,000
+89% +$190K 0.01% 824
2025
Q3
$228K Sell
34,873
-2,963
-8% -$15.9K ﹤0.01% 991
2025
Q2
$163K Buy
+37,836
New +$186K ﹤0.01% 1001
2025
Q1
– Sell
-15,967
Closed -$162K – 1222
2024
Q4
$162K Hold
15,967
– – ﹤0.01% 1042
2024
Q3
$199K Sell
15,967
-1,666
-9% -$20.7K ﹤0.01% 1069
2024
Q2
$229K Buy
17,633
+5,000
+40% +$82.8K 0.01% 1026
2024
Q1
$286K Sell
12,633
-6,667
-35% -$117K 0.01% 1047
2023
Q4
$250K Hold
19,300
– – 0.01% 1090
2023
Q3
$388K Buy
+19,300
New +$433K 0.01% 952

Other funds holding KPTI

Bridgeway Capital Management's KPTI Position: Q3 2026 in Review

Bridgeway Capital Management reduced its Karyopharm Therapeutics (KPTI) stake by 0.54% in Q3 2026, selling an estimated $1.6K and leaving 71,483 shares worth $87.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1145.

Bridgeway Capital Management first reported a position in KPTI in Q3 2023 and has held it in 12 quarters since. The position peaked at $702K in Q2 2026. 92 funds tracked by Wall St. Rank hold KPTI as of Q3 2026.

  • Bridgeway Capital Management held 71,483 shares of Karyopharm Therapeutics worth $87.2K as of Q3 2026.
  • Bridgeway Capital Management sold 390 Karyopharm Therapeutics shares in Q3 2026, an estimated $1.6K.
  • Karyopharm Therapeutics made up ﹤0.01% of Bridgeway Capital Management's portfolio in Q3 2026, its #1145 holding.
  • Bridgeway Capital Management first reported a position in Karyopharm Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Bridgeway Capital Management's Karyopharm Therapeutics position peaked at $702K in Q2 2026.
  • 92 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q3 2026.

Based on Bridgeway Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.